Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Sees Large Decrease in Short Interest

Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) saw a significant drop in short interest in August. As of August 31st, there was short interest totalling 1,290,000 shares, a drop of 20.4% from the August 15th total of 1,620,000 shares. Based on an average daily volume of 531,800 shares, the short-interest ratio is currently 2.4 days.

Hedge Funds Weigh In On Brainstorm Cell Therapeutics

An institutional investor recently bought a new position in Brainstorm Cell Therapeutics stock. Kingswood Wealth Advisors LLC purchased a new position in Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 81,050 shares of the biotechnology company’s stock, valued at approximately $46,000. Kingswood Wealth Advisors LLC owned approximately 0.12% of Brainstorm Cell Therapeutics at the end of the most recent quarter. Institutional investors own 14.33% of the company’s stock.

Brainstorm Cell Therapeutics Stock Performance

NASDAQ BCLI traded up $0.01 on Tuesday, hitting $0.27. 19,562 shares of the stock traded hands, compared to its average volume of 740,406. The business’s fifty day moving average is $0.33 and its two-hundred day moving average is $0.42. Brainstorm Cell Therapeutics has a 12 month low of $0.13 and a 12 month high of $1.08. The firm has a market capitalization of $19.19 million, a price-to-earnings ratio of -0.83 and a beta of 0.35.

Brainstorm Cell Therapeutics (NASDAQ:BCLI) last issued its quarterly earnings results on Wednesday, August 14th. The biotechnology company reported ($0.04) EPS for the quarter, meeting analysts’ consensus estimates of ($0.04). During the same period in the previous year, the firm posted ($0.27) EPS. Analysts expect that Brainstorm Cell Therapeutics will post -0.19 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on BCLI. StockNews.com initiated coverage on shares of Brainstorm Cell Therapeutics in a research report on Sunday. They issued a “hold” rating for the company. Maxim Group raised Brainstorm Cell Therapeutics from a “hold” rating to a “buy” rating and set a $2.00 price target for the company in a research report on Thursday, July 11th.

Brainstorm Cell Therapeutics Company Profile

Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.